|Day's Range||3.83 - 4.05|
|52 Week Range||1.82 - 8.15|
|PE Ratio (TTM)||-3.82|
|Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
We are initiating coverage of Agile Therapeutics, Inc. (AGRX) with a $7.00 valuation. The company’s lead product, Twirla® (AG200-15), is a once-weekly low-dose combination hormonal contraceptive patch. Agile has conducted a comprehensive development program for Twirla® that includes three Phase 3 clinical trials, and the company will be resubmitting the new drug application (NDA) during the first half of 2017.
On a per-share basis, the Princeton, New Jersey-based company said it had a loss of 26 cents. The results exceeded Wall Street expectations. The average estimate of three analysts surveyed by Zacks Investment ...
Agile Therapeutics, Inc. (AGRX) moved big last session, as its shares rose almost 14% on the day.